Generic Xerava Availability
Last updated on Jul 9, 2025.
Xerava is a brand name of eravacycline, approved by the FDA in the following formulation(s):
XERAVA (eravacycline dihydrochloride - powder;intravenous)
-
Manufacturer: TETRAPHASE PHARMS
Approval date: August 27, 2018
Strength(s): EQ 50MG BASE/VIAL [RLD] -
Manufacturer: TETRAPHASE PHARMS
Approval date: June 3, 2020
Strength(s): EQ 100MG BASE/VIAL [RLD]
Is there a generic version of Xerava available?
No. There is currently no therapeutically equivalent version of Xerava available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xerava. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Crystalline forms of eravacycline
Patent 10,961,190
Issued: March 30, 2021
Inventor(s): LaFrance Danny & Hogan Philip C. & Liu Yansheng & He Minsheng & Chen Chi-Li & Niu John
Assignee(s): Tetraphase Pharmaceuticals, Inc.The invention relates to crystalline forms of the bis-HCI salt of a compound represented by Structural Formula 1, and pharmaceutical compositions comprising crystalline forms of the bis-HCL salt of a compound represented by Structural Formula 1 described herein. The crystalline forms of the bis-HCl salt of a compound of Structural Formula 1 and compositions comprising the crystalline forms of the compound of Structural Formula 1 provided herein, in particular, crystalline Form I, crystalline Form J, crystalline Form A, and crystalline Form B, or mixtures thereof, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders. Also described herein are methods for preparing the crystalline forms (e.g., Forms I, J, B and A) of the bis-HCI salt of a compound represented by Structural Formula 1.
Patent expiration dates:
- October 19, 2037✓
- October 19, 2037
-
Crystalline forms of eravacycline
Patent 11,578,044
Issued: February 14, 2023
Inventor(s): LaFrance; Danny et al.
Assignee(s): Tetraphase Pharmaceuticals, Inc. (Waltham, MA)The invention relates to crystalline forms of the bis-HCl salt of a compound represented by Structural Formula 1, and pharmaceutical compositions comprising crystalline forms of the bis-HCL salt of a compound represented by Structural Formula 1 described herein. The crystalline forms of the bis-HCl salt of a compound of Structural Formula 1 and compositions comprising the crystalline forms of the compound of Structural Formula 1 provided herein, in particular, crystalline Form I, crystalline Form J, crystalline Form A, and crystalline Form B, or mixtures thereof, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders. Also described herein are methods for preparing the crystalline forms (e.g., Forms I, J, B and A) of the bis-HCl salt of a compound represented by Structural Formula 1.
Patent expiration dates:
- October 19, 2037✓
- October 19, 2037
-
C7-fluoro substituted tetracycline compounds
Patent 8,796,245
Issued: August 5, 2014
Inventor(s): Zhou Jingye & Xiao Xiao-Yi & Plamondon Louis & Hunt Diana Katharine & Clark Roger B. & Zahler Robert B.
Assignee(s): TetraPhase Pharmaceuticals, Inc.The present invention is directed to a compound represented by Structural Formula (A):
Patent expiration dates:
- August 7, 2029✓
- August 7, 2029
-
C7-fluoro substituted tetracycline compounds
Patent 8,906,887
Issued: December 9, 2014
Inventor(s): Zhou Jingye & Xiao Xiao-Yi & Plamondon Louis & Hunt Diana Katharine & Clark Roger B. & Zahler Robert B.
Assignee(s): Tetraphase Pharmaceuticals, Inc.The present invention is directed to a compound represented by Structural Formula (A):
Patent expiration dates:
- December 28, 2030✓
- December 28, 2030
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- August 27, 2023 - NEW CHEMICAL ENTITY
- August 27, 2028 - GENERATING ANTIBIOTIC INCENTIVES NOW
More about Xerava (eravacycline)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: tetracyclines
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.